

# Zhi-Ming Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2265539/publications.pdf>

Version: 2024-02-01

76  
papers

995  
citations

516561

16  
h-index

526166

27  
g-index

76  
all docs

76  
docs citations

76  
times ranked

1478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling. <i>Clinical Cancer Research</i> , 2019, 25, 1867-1879.	3.2	154
2	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2670-2681.	0.6	77
3	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. <i>Oncotarget</i> , 2016, 7, 33035-33045.	0.8	46
4	High Ki67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. <i>European Journal of Haematology</i> , 2012, 88, 510-517.	1.1	39
5	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index of Overall Survival in Cisplatin-based Chemotherapy-treated Patients with Metastatic Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 809-815.	1.2	39
6	Prognostic Value of Interim and Posttherapy <sup>18</sup> F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas. <i>Journal of Nuclear Medicine</i> , 2013, 54, 507-515.	2.8	35
7	Expressions and prognostic values of the <i>E2F</i> transcription factors in human breast carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 3521-3532.	0.9	35
8	A single-cell atlas of diffuse large B cell lymphoma. <i>Cell Reports</i> , 2022, 39, 110713.	2.9	33
9	Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors. <i>BMC Cancer</i> , 2010, 10, 358.	1.1	32
10	SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. , 2020, 8, e001037.		27
11	Serum beta2-microglobulin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1265-1270.	0.8	25
12	The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma. <i>PeerJ</i> , 2016, 4, e1742.	0.9	25
13	A TNM Staging System for Nasal NK/T-Cell Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0130984.	1.1	21
14	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2019, 134, 755-755.	0.6	21
15	Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells. <i>Cancer Biology and Therapy</i> , 2008, 7, 51-60.	1.5	20
16	Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. <i>International Journal of Hematology</i> , 2011, 94, 178-184.	0.7	19
17	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. <i>PLoS ONE</i> , 2015, 10, e0133973.	1.1	17
18	Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 2589.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Annals of Hematology</i> , 2015, 94, 1865-1873.	0.8	14
20	Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 34.	4.9	14
21	Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis. <i>Cancer Medicine</i> , 2018, 7, 1845-1851.	1.3	14
22	Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2020, 136, 1-1.	0.6	13
23	Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy. <i>Chinese Journal of Cancer</i> , 2015, 34, 70-78.	4.9	12
24	High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. <i>Oncotarget</i> , 2016, 7, 35404-35411.	0.8	12
25	Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites. <i>Chinese Journal of Cancer</i> , 2012, 31, 342-347.	4.9	12
26	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	1.3	12
27	Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 608-13.	4.9	11
28	A comparison of R-EPOCH and R-CHOP as a first-line regimen in <i>de novo</i> DLBCL patients with high Ki-67 expression in a single institution. <i>Oncotarget</i> , 0, 7, 41242-41250.	0.8	11
29	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. <i>Blood</i> , 2020, 136, 43-43.	0.6	11
30	High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0152842.	1.1	11
31	Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex. <i>Blood</i> , 2019, 134, 1569-1569.	0.6	10
32	Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2016, 95, 19-26.	0.8	9
33	High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. <i>Cancer Medicine</i> , 2019, 8, 1359-1367.	1.3	9
34	Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China. <i>Journal of Hematology and Oncology</i> , 2021, 14, 131.	6.9	9
35	Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase Sandwich With Radiotherapy in Localized Natural Killer/T Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 766200.	2.2	9
36	The role of protein p16INK4a in non-opharyngeal head and neck squamous cell carcinoma in Southern China. <i>Oncology Letters</i> , 2018, 16, 6147-6155.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis. <i>Cancer Medicine</i> , 2019, 8, 874-881.	1.3	8
38	Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 127-135.	1.2	8
39	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. <i>Blood Advances</i> , 2022, 6, 2731-2744.	2.5	8
40	Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. <i>Scientific Reports</i> , 2016, 6, 23996.	1.6	7
41	Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma. <i>Cancer Medicine</i> , 2019, 8, 4688-4698.	1.3	7
42	High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL). <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 121-127.	1.1	7
43	Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma. <i>Leukemia Research</i> , 2021, 111, 106705.	0.4	7
44	Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Frontiers in Oncology</i> , 2021, 11, 607145.	1.3	6
45	Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	5
46	Review on natural killer/T-cell lymphoma. <i>Hematological Oncology</i> , 2023, 41, 221-229.	0.8	5
47	Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 835103.	2.2	5
48	Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 264-71.	4.9	4
49	Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2020, 99, 1311-1319.	0.8	4
50	Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110 $\beta$ , for treating relapsed or refractory non-Hodgkin's lymphoma. <i>Oncotarget</i> , 2015, 6, 44049-44056.	0.8	3
51	Core Needle Biopsy Targeting the Viable Area of Deep-Sited Dominant Lesion Verified by Color Doppler and/or Contrast-Enhanced Ultrasound Contribute to the Actionable Diagnosis of the Patients Suspicious of Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 500153.	1.3	3
52	Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis. <i>Hematological Oncology</i> , 2023, 41, 248-256.	0.8	3
53	Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. <i>Cancer Medicine</i> , 2022, 11, 4134-4145.	1.3	3
54	Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 313-325.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Rinsing sampling of core needle biopsy for flow cytometric analysis: A favorable method for lymphoma diagnosis. <i>Cancer Medicine</i> , 2020, 9, 9336-9345.	1.3	2
56	Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma. <i>Hematological Oncology</i> , 2021, 39, 625-638.	0.8	2
57	The beneficial effect of Escalated-dose CHOP for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study. <i>Cancer Medicine</i> , 2021, 10, 7650-7664.	1.3	2
58	Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis. <i>Annals of Hematology</i> , 2022, 101, 595-605.	0.8	2
59	Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination. <i>Frontiers in Oncology</i> , 2022, 12, 796738.	1.3	2
60	Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL. <i>Annals of Hematology</i> , 2021, 100, 2293-2302.	0.8	1
61	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2. <i>Journal of Cancer</i> , 2021, 12, 2059-2064.	1.2	1
62	Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma. <i>Blood</i> , 2015, 126, 1521-1521.	0.6	1
63	Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series. <i>Blood</i> , 2021, 138, 1399-1399.	0.6	1
64	Single-Arm Phase 1b/2 Trial of the PI3K Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 2483-2483.	0.6	1
65	Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study. <i>Blood</i> , 2020, 136, 52-53.	0.6	1
66	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. <i>Blood</i> , 2020, 136, 38-38.	0.6	1
67	Apoptosis induced by DNA primase inhibitor 3,3'-diethyl-9-methylthia-carbocyanine iodide in human leukemia HL-60 cells. <i>Yaoxue Xuebao</i> , 2006, 41, 978-84.	0.2	1
68	SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7525-7525.	0.8	1
69	Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma--a Single Center Experience. <i>Blood</i> , 2015, 126, 3936-3936.	0.6	0
70	Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial. <i>Blood</i> , 2016, 128, 1819-1819.	0.6	0
71	PET/CT alone versus PET/CT and MRI-guided therapy in patients with upper aerodigestive tract natural killer/T-cell lymphoma, nasal type: A prospective study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7537-7537.	0.8	0
72	A Phase1b Clinical Study of the Oral PI3K Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 3576-3576.	0.6	0

#	ARTICLE	IF	CITATIONS
73	A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2021, 138, 1386-1386.	0.6	0
74	Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China. Blood, 2020, 136, 1-1.	0.6	0
75	The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma. Blood, 2020, 136, 14-16.	0.6	0
76	Prompt assessment of tumor load and treatment response in patients with lymphoma by a blood-based multiomics approach.. Journal of Clinical Oncology, 2022, 40, e19547-e19547.	0.8	0